A Randomized and Open-label Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of LY01005 Versus Goserelin Comparator (ZOLADEX) Following a Single Administration in Patients With Prostate Cancer
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Goserelin (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Luye Pharma Group
- 04 Jan 2019 Status changed from active, no longer recruiting to completed.
- 17 Oct 2018 Planned End Date changed from 30 Nov 2018 to 30 Dec 2018.
- 28 Aug 2018 Planned End Date changed from 30 Sep 2018 to 30 Nov 2018.